What Did the Tesamorelin Phase 3 Trials Report?
Short answer: In adults with HIV-associated abdominal fat accumulation, the phase 3 trials published by Falutz and colleagues in the New England Journal of Medicine in 2007 and in a pooled analysis in 2010 reported visceral adipose tissue, measured by CT, falling by about 15% over 26 weeks in the tesamorelin groups while it rose slightly in the placebo groups. IGF-1 rose and the effect reversed when the compound was stopped.
The trials enrolled several hundred participants and used CT scanning of the abdomen as the primary measure, which is why the result is stated as a change in visceral fat rather than in weight. Subcutaneous fat changed little.
These are the trials behind the 2010 approval. They are cited here as published science; the pack is supplied for laboratory research and no guidance is given on its use.
REVIVE LAB UAE supplies the pack for laboratory research use only. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.
Tesamorelin Pack 20 mg — REVIVE LAB UAE
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Tesamorelin Pack UAE — Live Stock & Pricing
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Tesamorelin Pack UAE — Live Stock & Pricing
Research-Use Only Disclaimer: This page is published for laboratory and scientific research information purposes only. Nothing here constitutes medical advice, dosing guidance, or a therapeutic recommendation. Products supplied by REVIVE LAB UAE (revivelab.ae) — where applicable — are sold strictly as reference materials for research use, not for human or veterinary consumption. Buyers and readers are solely responsible for compliance with applicable UAE laws and institutional research ethics requirements.